Ten Thousand Disposable Prostate Surgery Hands Sitting in Hospital Closets

The strangest number in this story is 10,000. That is how many single-use surgical handpieces — the disposable tips on a robot that shaves away an enlarged prostate — PROCEPT BioRobotics allegedly had sitting in hospital storage rooms across the United States as of February 2026. Not on operating tables. Not being sterilized for tomorrow's surgery. Just sitting there. In cabinets. Expired or nearly expired, presumably, because these things have a shelf life. Ten thousand hands that were never used.

That is weird. A single-use medical consumable, by definition, cannot be inventory. Or at least it shouldn't be, not at scale. You don't stockpile the thing you throw away after one use the way you stockpile printer cartridges or auto parts. You order as you need it.

Except apparently you do, if the price is right.

This is basically trade financing in surgical clothing. The mechanics are straightforward: PROCEPT offered undisclosed bulk discounts to hospitals, specifically in the final weeks of each quarter, to incentivize them to place large orders for handpieces they did not yet need. The hospital gets a discount. PROCEPT books the revenue immediately. The catch — the one the complaint alleges PROCEPT did not disclose — is that revenue booked today is revenue stolen from tomorrow. You cannot eat tomorrow's dinner today and still claim tomorrow you will be hungry.

The official label for what PROCEPT was doing was "strong commercial execution." The economic reality was closer to a loan: the discount was the interest rate, and the borrowed principal was future demand.

The plumbing of PROCEPT's business model makes this especially perverse. The company sells the AquaBeam (later HYDROS) robotic system to hospitals for roughly $500,000 each. That is the razor. The blade is the handpiece — a single-use consumable priced around $3,300 to $3,500 per unit. By FY2025, handpiece and consumable revenue made up approximately 60% of total revenue. Investors cared about handpiece unit sales not because the company was running a hardware business but because each handpiece sold was supposed to represent one actual procedure performed on one actual patient. Handpiece volume was a proxy for utilization, and utilization was a proxy for adoption, and adoption was the only thing justifying the stock's triple-digit price.

So when the CFO told investors in May 2024 that customers "tend to order as they need product" and that PROCEPT did not have "large stocking orders," he was describing an ordering pattern that, according to the complaint, was already fiction.

The truth came out in three installments, each accompanied by a stock drop of roughly the magnitude you would expect if you realized the revenue you were pricing was partly a mirage.

August 6, 2025. PROCEPT reported Q2 FY2025 results. Handpiece sales unexpectedly deteriorated. The company lowered Q3 shipment guidance to ~13,350 units, below consensus. Stock fell 16% over two days, from $45.69 to $38.41. The market's first question: why did unit sales miss? The company's answer at the time was vague.

November 4, 2025. Q3 results again missed on handpiece units — 13,225 sold, still weak. But now management said something new: they were reducing annual guidance by 1,000 units to allow for "optimization of field inventory." CEO Larry Wood admitted some customers were "probably carrying too much" inventory. Stock dropped another 10%, from $35.02 to $31.30. "Optimization of field inventory" is securities-law-speak for "we shipped stuff to customers that they don't need and now we can't sell them more." The market's second question: how much inventory did you leave in the channel? The company still did not answer.

February 25, 2026. This is the one that broke the dam. Q4 results revealed that U.S. handpiece sales had materially exceeded the number of actual procedures performed in every single quarter since Q1 2023. Cumulative excess field inventory: over 10,000 units. Sequential contraction in U.S. handpiece sales: approximately 30%. The company announced it was eliminating the historical practice of providing bulk handpiece discounts in the final weeks of quarters. Stock fell 18%, from $27.84 to $22.69.

Over that two-day period in late February, the stock declined $5.15 per share. But the cumulative decline from the August 2025 high was $22.06, or nearly 48%. From the class period high — which appears to have been north of $100 per share based on the lawsuit's claim of a 75%+ decline — the loss exceeded $75 per share. As of August 7, 2026, PRCT trades at $20.41.

The math tells you everything. A stock that went from over $100 to $20 in 18 months is a stock whose valuation was built on a growth narrative that turned out to be, in part, borrowed growth.

Here is the tiny dialogue that clarifies the incentives:

Hospital purchasing manager: "If I buy 500 handpieces today instead of 50 per month for the next year, I get a discount on every one. My budget cycle looks great. My procedure volume doesn't change. Win-win."

PROCEPT sales team: "If we book $1.65 million in handpiece revenue today instead of spreading it over 12 months, we hit our quarterly target. Our gross margin takes a hit from the discount, but that is invisible if we don't disclose the discount. Win-win."

Investor who bought PRCT at $80: "I thought handpiece volume was a signal of genuine demand. I was wrong. Win for neither of us."

The hospital and the sales team had perfectly aligned incentives. The investor was the residual claimant, which is another way of saying the investor was the person who gets paid last — or in this case, not at all.

Is this fraud? That is ultimately for a court in the Northern District of California to decide. The complaint alleges violations of Section 10(b) of the Securities Exchange Act and Rule 10b-5 — false or misleading statements, or material omissions, that caused investor losses. The class period runs from February 28, 2024, through February 25, 2026. The lead plaintiff deadline is September 22, 2026.

But the more interesting question structurally is not whether this was legally fraudulent. It is why the market rewarded it for so long.

The answer is that PROCEPT's revenue model — consumable-driven recurring revenue — is one of the most valued business models in medtech. It looks like SaaS. It looks like a razor-and-blade. It looks like predictability. Investors love it. And because investors love it, they are extraordinarily slow to question whether the "recurring" part is genuine or whether the "consumable" is actually sitting in a closet.

The discount program worked for a while precisely because the market was not looking at channel inventory. It was looking at top-line revenue growth, which was real — just temporally displaced. Revenue booked in Q2 2024 that would have naturally been booked in Q4 2024 still counts as revenue in Q2. It still grows the year-over-year number. It still hits the guidance. It just cannibalizes the future.

This is old finance. It is the same mechanism that drives end-of-quarter loan originations at mortgage banks, or channel stuffing at PC manufacturers in the 1990s, or revenue recognition disputes at every software company that has ever had a "services" line item. The label changes. The plumbing does not.

There is a glimmer of normalization. In Q2 2026, PROCEPT reported that the ratio of handpieces sold to U.S. procedures performed was approximately 98%. That is roughly one-for-one. The channel is clearing. Procedures are growing — 13,100 in Q2 2026, up 21% year-over-year. The company is pricing handpieces higher, at $3,550 per unit, upfrom roughly $3,200 a year ago. Gross margin expanded to 66%.

But here is the thing about normalization: it only looks healthy in comparison to what came before. A 98% handpiece-to-procedure ratio is not a sign of extraordinary commercial execution. It is a sign that the company is no longer booking phantom revenue. It is the floor, not the ceiling.

And the revenue growth that investors get now — FY2026 guidance of $390–$410 million, or 27–33% year-over-year — is growth unamplified by discount-driven pull-forward. It is organic. It is real. It is also significantly slower than the 45%+ growth rates the market was pricing in when the stock stood above $100.

The structural implication is simple: PROCEPT is a company whose valuation was partly built on revenue that did not exist. The revenue never existed in the quarter it was booked. It was time-traveled. And now that the time machine is broken, the stock is worth roughly what the underlying procedure growth justifies, which is a number closer to $20 than to $100.

The question for anyone still holding PRCT is not whether the lawsuit will be settled or dismissed. The question is whether the procedure growth story — 54,000 to 56,000 U.S. procedures guided for FY2026 — is enough on its own to make the stock meaningfully appreciate from here. That is a bet on AquaBeam adoption, not on accounting creativity. And that is a much narrower, much harder, and much more honest bet than the one the market was making two years ago.

Ten thousand unused hands in hospital closets. That is the weirdest part of this story. But it is also the most informative part, because it tells you exactly what fraction of the revenue growth was real and what fraction was a discount disguised as demand.

The rest is just plumbing.